2015 American Transplant Congress
Safety and Efficacy of All Oral DAA Therapy for Genotype 1 HCV Post-Liver Transplant: Interval Results from the HCV-TARGET Multicenter Prospective Observational Study
The safety and efficacy of direct-acting antivirals (DAA) for HCV post-LT remain unknown. METHODS: We describe the safety and efficacy of all oral DAA-therapy for…2015 American Transplant Congress
Sofosbuvir Therapy in Early and Late Post Liver Transplant Setting: A Single Center Experience
Background: Hepatitis C (HCV) treatment has entered a new phase of excitement with new oral therapies. Here we describe our experience of sofosbuvir (SOF) based…2015 American Transplant Congress
Changes in Utilization, Discard, and Outcomes Associated With Hepatitis C (+) Donor Livers in the Era of Direct Acting Anti-Retroviral Therapy
Johns Hopkins University, Baltimore, MD.
While 45% of liver candidates are hepatitis C (HCV) (+) and might benefit from an HCV (+) donor liver, only 7.1% receive one, and HCV…2015 American Transplant Congress
Pretransplant Hepatitis B Viral Infection Increased Risk of Death After Kidney Transplantation
Clinical outcomes have not been well evaluated in kidney transplant recipients (KTRs) with hepatitis B virus (HBV). Here, we aimed to investigate the recent posttransplant…2015 American Transplant Congress
The Impact of the New Antivirals Sofosfuvir/Ledipasvir on Liver Transplantation for Hepatitis C Cirrhosis
The approval of potent antiviral therapy (AVT) with sofosfuvir/ledipasvir (sof/ldv) for hepatitis C (HCV) dramatically increased cure rates (SVR) to nearly 100%. A recent prospective…2015 American Transplant Congress
Pre-Liver Transplant Urinary Proteome Analysis Does Not Predict Development of Chronic Kidney Disease After Transplantation
Background and aims: Chronic kidney disease (CKD) is a common complication after liver transplantation. Kidney biopsies cannot be easily performed before liver transplantation to predict…2015 American Transplant Congress
Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Co-Infected Recipients: The Real World Experience
End stage liver disease is a frequent cause of mortality in patients with HIV. Though demonstrated in the NIH observational trial, the effectiveness of LT…2015 American Transplant Congress
The Impact of HCV on Post Transplant Biliary Strictures
Tampa General Medical Group, Tampa.
Biliary strictures continue to be a significant cause of morbidity following liver transplantation (LT). Though several studies have implicated donor and recipient factors in the…2015 American Transplant Congress
Post-Liver Transplant Metabolic Syndrome Increases the Risk of Recurrent Fibrosis in Patients With Hepatitis C
Department of Medicine, Columbia University, New York, NY.
Introduction: Post-liver transplant (LT) metabolic syndrome (MS) is common and may impact fibrosis progression in LT recipients with hepatitis C virus (HCV). Methods: All adults…2015 American Transplant Congress
Liver Transplantation for Hepatocellular Carcinoma inside Milan Criteria: Lower Recurrence in Patients With Hepatitis C Infection
Mayo Clinic, Jacksonville, FL.
Purpose: Hepatitis C infection (HCV) related-cirrhosis can lead to hepatocellular carcinoma (HCC). Liver transplantation (LT) is the optimal treatment for selected patients with HCC, providing…